S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY

S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY

Bibliographic Details
Main Authors:	W. Townsend, W. Hiddemann, C. Buske, G. Cartron, D. Cunningham, M. J. Dyer, J. Gribben, E. Phillips, M. Dreyling, J. F. Seymour, A. Grigg, T.-Y. Lin, X.-N. Hong, D. Kingbiel, T. G. Nielsen, A. Knapp, M. Herold, R. Marcus
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843716.68800.8b

Similar Items

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
by: William Townsend, et al.
Published: (2023-07-01)

Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis
by: Bellone M, et al.
Published: (2021-07-01)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
by: Andrew Grigg, et al.
Published: (2017-04-01)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
by: Michael Herold, et al.
Published: (2022-03-01)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
by: Carol Moreno, et al.
Published: (2022-01-01)

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
by: John F. Seymour, et al.
Published: (2019-06-01)

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
by: John F. Seymour, et al.
Published: (2020-05-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system
by: Wenwang Lang, et al.
Published: (2025-01-01)

Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
by: Paul J. Hengeveld, et al.
Published: (2025-01-01)

PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
by: Silvana Novelli, et al.
Published: (2023-08-01)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-04-01)

Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study
by: Véronique Leblond, et al.
Published: (2018-11-01)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
by: Ocvirk Janja, et al.
Published: (2016-06-01)

Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Published: (2022-06-01)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-10-01)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
by: Judith Trotman, et al.
Published: (2023-08-01)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024-10-01)

Real‐world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non‐small cell lung cancer
by: Ayami Kaneko, et al.
Published: (2024-05-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
by: Xiaohui Zeng, et al.
Published: (2019-12-01)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022-08-01)

Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study
by: Guanghua Chu, et al.
Published: (2021-02-01)

Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
by: Moe, M, et al.
Published: (2008)

Cost–effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma
by: Jun Ma, et al.
Published: (2023-11-01)

Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC
by: Edward S. Kim, MD, et al.
Published: (2022-01-01)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
by: Xue-Song Sun, et al.
Published: (2020-08-01)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
by: Andrea Visentin, et al.
Published: (2022-11-01)

A meta-analysis of Pemetrexed plus Platinum Chemotherapy versus Gemcitabine plus Platinum Chemotherapy for Advanced Non-small Cell Lung Cancer
by: Jin JIANG, et al.
Published: (2011-01-01)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
by: Yu‐Wen Zhou, et al.
Published: (2021-05-01)

Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo
by: Xue C, et al.
Published: (2016-03-01)

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
by: Laurie H. Sehn, et al.
Published: (2020-06-01)

Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
by: Marlise R. Luskin, et al.
Published: (2025-02-01)

Surgery plus chemotherapy versus chemotherapy alone in primary intestinal lymphoma: a meta-analysis
by: Yefei Shu, et al.
Published: (2021-11-01)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
by: Steven Le Gouill, et al.
Published: (2023-08-01)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
by: Stephan Stilgenbauer, et al.
Published: (2020-10-01)

Fasting-mimicking diet plus chemotherapy in breast cancer treatment
by: Claudio Vernieri, et al.
Published: (2020-08-01)

Comparison of the efficacy and safety of neoadjuvant PD-1 inhibitors plus chemotherapy vs targeted therapy plus chemotherapy in locally advanced hypopharyngeal squamous cell carcinoma
by: Wen Gao, et al.
Published: (2024-10-01)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
by: Enrique Grande, et al.
Published: (2023-12-01)

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2019-05-01)

Laparoscopic Hyperthermic Intraperitoneal Chemotherapy plus Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer with Malignant Ascites
by: Hsing-Wei Yu, et al.
Published: (2024-10-01)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
by: Zong Y, et al.
Published: (2020-12-01)